Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule

Acta Haematologica

Volumn 99, Issue 2, 1998, Pages 106-108

  Munker, Reinhold ^a,b   Kantarjian, Hagop ^a   O'Brien, Susan ^a   Keating, Michael ^a   Andreeff, Michael ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; MOUTH ULCER; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPTICEMIA; STOMATITIS;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; PACLITAXEL;

EID: 0031885127     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040822     Document Type: Article

References (8)

1. Foa R, Norton L, Seidman AD: Taxol (paclitaxel): A novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994;24:6-14.
2. Lassus M, Scott D, Leyland-Jones B: Allergie reactions associated with Cremophor-containing antineoplastics. Proc Am Soc Clin Oncol 1985;4:268-275.
3. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10:1165-1170.
4. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988;48:4093-4100.
5. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-568.
6. Gangemi RMR, Tiso M, Marchetti C, Severi AB, Fabbi M: Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 1995;36:385-392.
7. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989;49:4640-4647.
8. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute leukemias. Blood 1996;88:756.